Targeted therapy in thyroid cancer: molecular alterations and clinical management - PubMed
5 hours ago
- #Targeted Therapy
- #Thyroid Cancer
- #Molecular Alterations
- Targeted therapies in thyroid cancer are based on molecular alterations like BRAF V600E, RET mutations/fusions, and NTRK fusions.
- BRAF/MEK inhibitors are used for BRAF-mutant ATC, while selective RET or TRK inhibitors treat fusion-positive tumors.
- For tumors without specific markers, VEGFR-targeted multikinase inhibitors (e.g., lenvatinib) remain standard for radioiodine-refractory DTC.
- Redifferentiation therapies aim to restore radioiodine sensitivity, and emerging pathways (e.g., PI3K/AKT/mTOR) offer new combination strategies.
- Early comprehensive genomic profiling is crucial to optimize treatment selection and overcome resistance across thyroid cancer subtypes.